Press release
Glioblastoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharma
Glioblastoma Pipeline Insight 2025
According to DelveInsight, the Glioblastoma treatment pipeline includes over 180 key companies actively engaged in developing more than 200 therapeutic candidates for the condition.
Glioblastoma Overview:
Glioblastoma Multiforme (GBM) is the most prevalent primary brain tumor in adults and is known for its extremely poor prognosis, despite improvements in diagnostic tools and treatment strategies. The disease progresses through somatic evolution, where genetic mutations accumulate, causing the tumor cells' genome to differ significantly from that of normal cells. GBM arises from a complex interplay of molecular and genetic changes that disrupt key signaling pathways. Its aggressive behavior is driven by its ability to infiltrate surrounding brain tissue, making full surgical removal nearly impossible, and by its high degree of vascularization, which contributes to its malignancy.
Patients with GBM often experience vague symptoms such as headaches, personality changes, nausea, or symptoms resembling a stroke. Common neurological manifestations include vomiting, seizures, cognitive impairments, focal deficits, and cranial nerve dysfunction. In rare instances, vertigo or psychiatric symptoms may occur. GBM accounts for approximately 52% of all primary brain tumors and 20% of all tumors within the cranial cavity, making it the most common and aggressive form of primary brain cancer.
Request for a detailed insights report on Glioblastoma pipeline insights [https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Glioblastoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Glioblastoma Therapeutics Market.
Key Takeaways from the Glioblastoma Pipeline Report
*
DelveInsight's Glioblastoma pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Glioblastoma treatment.
*
In March 2025, Laminar Pharmaceuticals revealed a Phase 2 clinical trial for LAM561 and TMZ. The planned Phase IIB/III randomized, double-blind, placebo-controlled study in patients with newly diagnosed primary glioblastoma multiforme (ndGBM) seeks to evaluate the efficacy and safety of LAM561 versus placebo, in combination with the standard treatment of radiation therapy and temozolomide (TMZ). This will be followed by a six-month adjuvant treatment period with TMZ and then LAM561 or placebo as monotherapy.
*
In March 2025, TVAX Biomedical announced Phase 2 and 3 clinical trials for Temozolomide. This randomized study aims to compare the combination of TVI-Brain-1 immunotherapy with standard therapy against standard therapy alone for newly diagnosed MGMT unmethylated glioblastoma patients. The treatment involves using the patient's own cancer cells, collected post-surgery, to create a vaccine that stimulates an immune response, significantly boosting the number of cancer neoantigen-specific effector T cell precursors in the patient's body.
*
Key Glioblastoma companies such as Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharmaceuticals, Vaximm, Inovio Pharmaceuticals, Mustang Bio, Bullfrog AI Holdings, Cantex, Chimeric Therapeutics, Philogen, Boehringer Ingelheim, Photonamic GmbH, Berg Pharma, Beyond Bio, Genenta Science, Polaris Pharmaceuticals, Telix Pharmaceuticals, Shanghai Simnova Biotechnology, NEONC Technologies, and others are evaluating new drugs for Glioblastoma to improve the treatment landscape.
*
Promising Glioblastoma pipeline therapies in various stages of development include Enzastaurin, Asunercept, Berubicin, VXM01, Azeliragon, MB-101, and others.
Glioblastoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Glioblastoma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Glioblastoma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Glioblastoma market.
Download our free sample page report on Glioblastoma pipeline insights [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Glioblastoma Emerging Drugs
*
Enzastaurin: Denovo BioPharma
*
Asunercept: Apogenix
*
Berubicin: CNS Pharmaceuticals
*
VXM01: VAXIMM
*
Azeliragon: Cantex
*
MB-101: Mustang Bio
Glioblastoma Companies
More than 180 major companies are actively involved in developing treatments for Glioblastoma. Among them, Denovo is one of the companies with drug candidates currently in the most advanced stage of development-Phase III clinical trials.
DelveInsight's report covers around 200+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Glioblastoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Glioblastoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Glioblastoma Therapies and Key Companies: Glioblastoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Glioblastoma Pipeline Therapeutic Assessment
- Glioblastoma Assessment by Product Type
- Glioblastoma By Stage
- Glioblastoma Assessment by Route of Administration
- Glioblastoma Assessment by Molecule Type
Download Glioblastoma Sample report to know in detail about the Glioblastoma treatment market @ Glioblastoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Glioblastoma Current Treatment Patterns
4. Glioblastoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Glioblastoma Late-Stage Products (Phase-III)
7. Glioblastoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Glioblastoma Discontinued Products
13. Glioblastoma Product Profiles
14. Glioblastoma Key Companies
15. Glioblastoma Key Products
16. Dormant and Discontinued Products
17. Glioblastoma Unmet Needs
18. Glioblastoma Future Perspectives
19. Glioblastoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Glioblastoma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/glioblastoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glioblastoma-clinical-trials-companies-therapeutic-assessment-therapies-treatment-algorithm-and-pipeline-analysis-denovo-biopharma-cantex-pharmaceuticals-cns-pharmaceuticals-canbridge-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Glioblastoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, and Pipeline Analysis | Denovo Biopharma, Cantex Pharmaceuticals, CNS Pharmaceuticals, CANbridge Pharma here
News-ID: 4084086 • Views: …
More Releases from ABNewswire
New Cosmology Book Challenges Science's Biggest Assumptions, Proposing the Big B …
Independent researcher Keith Taylor introduces the Void Energy-Regulated Space Framework (VERSF), offering a radical new lens on time, space, and the nature of ongoing creation.
What if the universe never stopped being created? What if the Big Bang wasn't simply an event locked away in the distant past but part of a process still unfolding today?
Keith Taylor asks these questions in his upcoming book, What if the Big Bang is Still…
Lipedema vs. Lymphedema: Symptoms, Diagnosis, and Treatment Options
Lipedema and lymphedema can both enlarge the limbs, but they arise from different biological problems and require different treatment strategies.
Moein Surgical Arts has published a comprehensive educational guide explaining the important differences between lipedema and lymphedema [https://moeinsurgicalarts.com/lipedema-vs-lymphedema/]-two chronic medical conditions that can cause limb enlargement, discomfort, reduced mobility, and significant changes in quality of life.
Although lipedema and lymphedema may appear similar, they develop for different biological reasons and often require…
Kieran J. Woll Redefines Modern Espionage Fiction With a Thriller That Asks What …
Kieran Woll Creative Works LLC unveils a sophisticated espionage narrative that challenges the conventions of the genre by embedding its threat not in a foreign government or rogue state but in the invisible architecture of daily life. The story follows Drake, Voss, and Raven as they confront a network designed to be undetectable and indestructible.
In an era when readers increasingly seek fiction that reflects the genuine complexities of the modern…
Craft Pilot Targets Three High-Growth Markets With Science-Backed Cognitive Well …
Craft Pilot is strategically expanding into the neurodivergent, gerontology, and corporate wellness sectors with products designed to engage the brain through tactile interaction and purposeful cognitive challenges. The company's science-informed approach is attracting growing interest from consumers and organizations seeking practical mental wellness solutions.
The conversation around wellness has evolved dramatically over the past decade. What was once dominated by gym memberships and dietary supplements now encompasses mental health, mindfulness, and…
More Releases for Glioblastoma
Glioblastoma Clinical Trial Pipeline Analysis: 150+ Key Companies Advancing the …
DelveInsight's Glioblastoma Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline glioblastoma therapies in different stages of clinical development. Major pharmaceutical and biotech companies are actively working to advance the glioblastoma pipeline landscape and improve future treatment possibilities for this highly aggressive brain cancer.
Key takeaways from the Glioblastoma Clinical Trial Landscape Report
• DelveInsight's glioblastoma pipeline report depicts a robust pipeline with 150+ active companies developing therapies for…
Key Trends Shaping the Future Glioblastoma Multiforme Market From 2025-2034: Adv …
Which drivers are expected to have the greatest impact on the over the glioblastoma multiforme market's growth?
The growing number of brain disorder cases is anticipated to boost the glioblastoma multiforme market in the coming years. A brain disorder is a condition that affects the brain's structure or function, leading to cognitive, emotional, or physical difficulties. The rise in brain disorder cases is attributed to factors such as an aging population,…
Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Glioblastoma Pipeline Insight, 2024," report provides comprehensive insights about 195+ companies and 210+ pipeline drugs in Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Glioblastoma Pipeline Report
* DelveInsight's Glioblastoma pipeline report depicts…
Glioblastoma Multiforme Market Insights, Forecast to 2031
"Glioblastoma Multiforme Market 2024,"
The objectives outlined in the report are multifaceted and aimed at offering a comprehensive understanding of the Glioblastoma Multiforme market dynamics. These objectives encompass a meticulous analysis and forecast of the market's dimensions, encompassing both its value and volume aspects. Additionally, the report seeks to discern and delineate the market shares held by major segments within the Glioblastoma Multiforme industry, providing stakeholders with a nuanced perspective on market…
Beyond Bravery - Bill Fitzpatrick's Fight Against Glioblastoma
Bill Fitzpatrick Jr, a retired sales professional from GE, has recently ventured into the world of writing with his debut book. Inspired by his experiences during taking care of his wife, who had Glioblastoma, Bill felt the need to share his journey and provide support to other families navigating similar challenges. In this article, we will dive into Bill's background, his motivation for becoming an author, details about his latest…
Recurrent Glioblastoma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Recurrent Glioblastoma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Recurrent Glioblastoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Recurrent Glioblastoma Pipeline Report
DelveInsight's Recurrent Glioblastoma…
